Peptides DB
Research-centric peptide and protocol reference hub

Research library

Every indexed study on every peptide in the database, with a machine summary and the numbers that matter pulled out. Filter on the left; the register updates as you go.

1724studies indexed776with human data107registered trials1479carry a numeric findingLibrarian added 0 studies today
Showing 4 studiesSortNewest indexed ▾
B
grade
SPARC: a structural pathogenicity algorithm for risk classification of hERG variants.
Cardiogen (AEDR) · Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology · 2026 · Observational · n=1727
SPARC identifies high-risk hERG variants using a structural pathogenicity score, potentially aiding in the interpretation of genetic testing results.
260 variants identified as high risk of pathogenicity with SPS ≥3.25.
B
grade
Echocardiographic risk stratification in heart failure with post-capillary pulmonary hypertension: prognostic value of LAVI and TAPSE/PASP.
Cardiogen (AEDR) · European heart journal. Cardiovascular Imaging · 2026 · Observational
LAVI and TAPSE/PASP are strong non-invasive predictors of adverse outcomes in heart failure with post-capillary pulmonary hypertension, potentially enhancing risk assessment beyond invasive methods.
HR 1.97, 95% CI 1.41-2.75; P < 0.0001
A
grade
Consistent Efficacy of Vutrisiran Across Sexes in Transthyretin Cardiac Amyloidosis: Evidence from the HELIOS-B Trial.
Cardiogen (AEDR) · European journal of heart failure · 2026 · RCT · Phase 3 · n=654
Vutrisiran appears to have consistent efficacy in reducing mortality and cardiovascular events in both men and women with ATTR-CM, though findings in women are less precise due to a smaller sample size.
Vutrisiran reduced the primary composite endpoint in women (HR 0.59, 95% CI 0.26-1.30) and men (HR 0.71, 95% CI 0.54-0.94; p-interaction = 0.66).
Showing 4 of 4